ʻO nā maʻi autoimmune, nā ʻano like ʻole a he mau maʻi refractory a koʻikoʻi, ʻo ia kekahi o nā kuhikuhi nui o ka hoʻomohala ʻana i ka lāʻau lapaʻau i kēia manawa.ʻO JAK-STAT kekahi o nā ala immunomodulatory liʻiliʻi i hōʻoia ʻia, ʻoi aku ka JAK inhibitors.Nui nā lāʻau lapaʻau,e like me tofacitinib, ua kūʻai ʻia ma ka honua holoʻokoʻa.

Ua hoʻomohala ʻia ka pahuhopu JAK no ka liʻiliʻi ma mua o 20 mau makahiki, akā i kēia manawa kokoke i 7 mau ʻano i ʻae ʻia no ke kūʻai ʻana.ʻO nā hōʻailona ka nui o nā maʻi ʻokoʻa a me nā maʻi pale ponoʻī, a ʻo nā hōʻailona hou i hoʻomaʻemaʻe ʻia ʻo ia ka nui o ka iwi marrow fibrosis a me ka rheumatoid arthritis.ʻO kēia ka mea e pili ana i ka mea hoʻopaneʻe JAK mua (tofacitinib) no ka mālama ʻana i ka maʻi rumatika.

ʻO Tofacitinib kahi mole liʻiliʻi waha JAK inhibitor i hoʻomohala ʻia e Pfizer.Loaʻa iā ia kahi koho JAK maikaʻi.I Nowemapa 2012, ua ʻae ka US FDA i ka facitinib citrate no ka mālama ʻana i ka methotrexate i lawa ʻole a i ʻole ka pane ʻole i ka lāʻau lapaʻau.ʻO kēia huahana ka JAK inhibitor mua i ʻae ʻia e ka FDA no ka mālama ʻana i ka maʻi rheumatoid arthritis.I kēia manawa, ma waho aʻe o nā hōʻailona i ʻāpono ʻia, ke hoʻāʻo ʻia nei ka tofacitinib no kona pono i ka ankylosing spondylitis, atopic dermatitis, keratoconjunctivitis sicca a me ka maʻi o Crohn.Ma ke ʻano o ke kūʻai aku ʻana o ka honua, ʻoi aku ka nui o ke kūʻai ʻana o tofacitinib ma 2017 ma mua o US $ 1 biliona, a ʻo ke kūʻai ʻana i kēlā me kēia makahiki ma 2019 ua hiki i ka US $ 2.242 biliona.

ʻO nā ala synthetic ʻokoʻa ka hopena nui i ka hopena a me ka maikaʻi o nā API.ʻO kā mākou synthesis o tofacitinib citrate e pale i ke ala patented.Pono ke ala synthetic i ke kumu kūʻai haʻahaʻa haʻahaʻa, nā hua kiʻekiʻe, nā haumia hoʻokahi a me ka maʻemaʻe hiki ke hoʻomalu ʻia i loko o kahi ākea kūpono, a hiki ke hoʻopili ʻia e nā mea kūʻai aku.No laila hiki iā mākou ke loaʻa ka pōmaikaʻi ma ka mākeke.I kēia manawa hiki i kā mākou hiki ke 50kg i kēlā me kēia mahina, a ua lawe ʻia ka tofacitinib citrate i USA, Mexico, Franch, Bangladesh, etc.